Dashboard
Manage Tickers

CPRX CATALYST PHARMACEUTICALS, INC.

Nasdaq catalystpharma.com


$ 21.25 $ -1.49 (-6.58 %)    

Thursday, 06-Nov-2025 10:19:37 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.32 $ -4.47 (-0.72 %)
DIA $ 470.68 $ -1.43 (-0.3 %)
SPY $ 674.37 $ -2.10 (-0.31 %)
TLT $ 89.72 $ 0.17 (0.18 %)
GLD $ 366.83 $ -0.37 (-0.1 %)
$ 21.38
$ 22.50
$ 21.15 x 2
$ 21.26 x 102
$ 21.02 - $ 22.80
$ 19.05 - $ 26.58
2,435,922
na
2.63B
$ 0.80
$ 12.08
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-26-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-15-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-16-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

catalyst-pharmaceuticals-raises-fy2025-sales-guidance-from-545000m-565000m-to-565000m-585000m-vs-562053m-est
Catalyst Pharmaceuticals Raises FY2025 Sal...
11/05/2025 21:18:37

Catalyst Pharmaceuticals (NASDAQ:CPRX) raises FY2025 sales outlook from $545.000 million-$565.000 million to $565.000 million-$...

catalyst-pharmaceuticals-q3-adj-eps-068-beats-033-estimate-sales-148392m-beat-136802m-estimate
Catalyst Pharmaceuticals Q3 Adj. EPS $0.68...
11/05/2025 21:18:19

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

what-does-the-market-think-about-catalyst-pharmaceuticals-inc
What Does the Market Think About Catalyst ...
10/21/2025 14:00:48

catalyst-pharmaceuticals-board-authorizes-200m-share-repurchase-program
Catalyst Pharmaceuticals Board Authorizes ...
10/01/2025 12:04:13

how-is-the-market-feeling-about-catalyst-pharmaceuticals
How Is The Market Feeling About Catalyst P...
09/09/2025 14:00:31

catalyst-pharmaceuticals-reaches-settlement-with-lupin-to-delay-generic-firdapse-launch-until-2035
Catalyst Pharmaceuticals Reaches Settlemen...
08/25/2025 12:06:03

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical co...

catalyst-pharmaceuticals-affirms-fy2025-sales-guidance-of-545000m-565000m-vs-561012m-est
Catalyst Pharmaceuticals Affirms FY2025 Sa...
08/06/2025 20:24:01

Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.000 million-$565.000 million to $545.000 million-...

catalyst-pharmaceuticals-q2-adj-eps-068-beats-038-estimate-sales-146563m-beat-140418m-estimate
Catalyst Pharmaceuticals Q2 Adj. EPS $0.68...
08/06/2025 20:23:43

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

catalyst-pharmaceuticals-applauds-nccn-guideline-update-adding-lems-diagnosis-and-amifampridine-support-for-sclc-patients
Catalyst Pharmaceuticals Applauds NCCN Gui...
08/06/2025 12:18:20

VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a support...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

is-the-market-bullish-or-bearish-on-catalyst-pharmaceuticals
Is the Market Bullish or Bearish on Cataly...
07/31/2025 20:00:36

peering-into-catalyst-pharmaceuticalss-recent-short-interest
Peering Into Catalyst Pharmaceuticals's Re...
07/14/2025 13:00:32

is-catalyst-pharmaceuticals-gaining-or-losing-market-support
Is Catalyst Pharmaceuticals Gaining or Los...
06/27/2025 19:00:22

top-3-health-care-stocks-youll-regret-missing-this-quarter
Top 3 Health Care Stocks You'll Regret Mis...
06/26/2025 12:15:48

catalyst-pharmaceuticals-affirms-fy2025-sales-guidance-of-54500m-56500m-vs-55724m-est
Catalyst Pharmaceuticals Affirms FY2025 Sa...
05/07/2025 20:50:43

Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.00 million-$565.00 million to $545.00 million-$56...

catalyst-pharmaceuticals-q1-adj-eps-068-beats-053-estimate-sales-14142m-beat-13086m-estimate
Catalyst Pharmaceuticals Q1 Adj. EPS $0.68...
05/07/2025 20:50:23

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

catalyst-pharmaceuticals-announces-health-canada-acceptance-of-agamree-new-drug-submission-with-priority-review-for-sub-licensee-kye-pharmaceuticals
Catalyst Pharmaceuticals Announces Health ...
04/08/2025 12:07:33

celsius-lucid-and-signet-are-among-top-10-mid-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio
Celsius, Lucid And Signet Are Among Top 10...
03/23/2025 21:28:30

Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%)...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION